<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03777410</url>
  </required_header>
  <id_info>
    <org_study_id>TRV-001</org_study_id>
    <nct_id>NCT03777410</nct_id>
  </id_info>
  <brief_title>Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma</brief_title>
  <official_title>Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Travera LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Hope Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Travera LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect bone marrow (BM) aspirate samples from patients with relapsed
      refractory multiple myeloma (RRMM) prior to the start of a new treatment regimen for the
      purposes of prospectively measuring single-cell mass accumulation rate (MAR) as a biomarker
      of patient response to that regimen.

      The primary study objective is to explore whether the single-cell MAR biomarker can predict
      patient response in RRMM patients. In order to enable this primary objective, two patient
      cohorts will be required. First, a small vanguard cohort of patients with treatment naïve
      disease to define drug concentrations used for testing, and second, the main RRMM patient
      cohort. Data will be collected to estimate the biomarker's predictive properties (accuracy,
      sensitivity, specificity), and to support improvement of the MAR biomarker through additional
      research and discovery within the study dataset.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best Response 4 months</measure>
    <time_frame>0-4 months</time_frame>
    <description>The best International Myeloma Working Group (IMWG) response of each patient over 4 months of therapy</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>Vanguard</arm_group_label>
    <description>Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapsed/Refractory MM</arm_group_label>
    <description>BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient's pursuing initial care for their multiple myeloma at one of the 7 study sites
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written Informed Consent provided by patient

          2. MM, with the following conditions:

        *For patients in the Vanguard cohort*

        1. Treatment naïve disease with BM clinically indicated

        *For patients in the RRMM cohort*

          1. Relapsed/refractory disease with BM samples clinically indicated

          2. Within 4-weeks prior to initiation of 2nd-line or later therapy

          3. Proceeding onto one of the following combination therapies [bortezomib (V),
             carfilzomib (K), lenalidomide (R), pomalidomide (P), cyclophosphamide (C),
             dexamethasone (d), ixazomib (I)]: RVd, VCd, KRd, PVd, KPd, Rd, Pd, Kd, IPd, IRd, RCd,
             PCd, venetoclax, Vd + venetoclax, Kd + venetoclax, selinexor+d

        Exclusion Criteria:

          1. Unable or unwilling to provide informed consent

          2. Daratumumab/Elotuzumab or other antibody-based therapeutic regimens as immediately
             planned treatment (as prior therapy is acceptable)

          3. Clinical trial with non-commercial relapsed/refractory samples as immediately planned
             treatment

          4. Prior exposure to chimeric antigen receptor T-cell (CAR-T) therapy

          5. Prior allogeneic stem cell transplant

          6. Has received any systemic chemotherapy or radiation therapy (RT), including
             palliative, within 7 days prior to BM biopsy

          7. Has received any Ab therapy within 4 weeks prior to BM biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil C Munshi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cara Rosenbaum, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Stevens, Ph.D.</last_name>
    <phone>6172999784</phone>
    <email>RRMMStudy@travera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurin Khan</last_name>
      <phone>626-218-0621</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Spivey</last_name>
      <phone>404-712-1739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Wright</last_name>
      <phone>617-724-5251</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Purvis</last_name>
      <phone>617-632-1950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine At Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Lieberman-Cribbin</last_name>
      <phone>212-241-7112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine - New York Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brielle Liotta</last_name>
      <phone>646-962-9336</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional</keyword>
  <keyword>biomarker</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>phenotypic</keyword>
  <keyword>biophysical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

